ES2322200T3 - Formulaciones en suspension que comprenden un principio activo, un tensioactivo poloxamero o meroxapol y un glicol, su uso para la fabricacion de un medicamento para tratar trastornos oftalmicos. - Google Patents

Formulaciones en suspension que comprenden un principio activo, un tensioactivo poloxamero o meroxapol y un glicol, su uso para la fabricacion de un medicamento para tratar trastornos oftalmicos. Download PDF

Info

Publication number
ES2322200T3
ES2322200T3 ES06759258T ES06759258T ES2322200T3 ES 2322200 T3 ES2322200 T3 ES 2322200T3 ES 06759258 T ES06759258 T ES 06759258T ES 06759258 T ES06759258 T ES 06759258T ES 2322200 T3 ES2322200 T3 ES 2322200T3
Authority
ES
Spain
Prior art keywords
composition
glycol
weight
meroxapol
ionic surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06759258T
Other languages
English (en)
Spanish (es)
Inventor
Geoffrey Robert Owen
Amy C. Brooks
Gustav Graff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of ES2322200T3 publication Critical patent/ES2322200T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES06759258T 2005-05-10 2006-05-08 Formulaciones en suspension que comprenden un principio activo, un tensioactivo poloxamero o meroxapol y un glicol, su uso para la fabricacion de un medicamento para tratar trastornos oftalmicos. Expired - Lifetime ES2322200T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67933205P 2005-05-10 2005-05-10
US679332P 2005-05-10

Publications (1)

Publication Number Publication Date
ES2322200T3 true ES2322200T3 (es) 2009-06-17

Family

ID=37081695

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06759258T Expired - Lifetime ES2322200T3 (es) 2005-05-10 2006-05-08 Formulaciones en suspension que comprenden un principio activo, un tensioactivo poloxamero o meroxapol y un glicol, su uso para la fabricacion de un medicamento para tratar trastornos oftalmicos.

Country Status (19)

Country Link
US (1) US20060257487A1 (enExample)
EP (1) EP1885336B1 (enExample)
JP (1) JP4968954B2 (enExample)
KR (1) KR20080011310A (enExample)
CN (1) CN101175475B (enExample)
AT (1) ATE428401T1 (enExample)
AU (1) AU2006244244B2 (enExample)
BR (1) BRPI0609227A2 (enExample)
CA (1) CA2607608A1 (enExample)
CY (1) CY1109117T1 (enExample)
DE (1) DE602006006308D1 (enExample)
DK (1) DK1885336T3 (enExample)
ES (1) ES2322200T3 (enExample)
MX (1) MX2007014083A (enExample)
PL (1) PL1885336T3 (enExample)
PT (1) PT1885336E (enExample)
SI (1) SI1885336T1 (enExample)
WO (1) WO2006121963A2 (enExample)
ZA (1) ZA200709251B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121964A2 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
US20070254841A1 (en) * 2006-01-25 2007-11-01 Ophthalmic Research Associates, Inc. Formulations and methods for treating dry eye
US20100130580A1 (en) * 2006-01-25 2010-05-27 Aciex Therapeutics, Inc. Formulations and Methods for Treating Dry Eye
US20090010850A1 (en) * 2007-05-24 2009-01-08 Ousler Iii George W Formulations and methods for treating dry eye
TW200812575A (en) * 2006-04-28 2008-03-16 Alcon Inc Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
US20090105245A1 (en) * 2006-12-21 2009-04-23 Bingaman David P Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor
TW201023912A (en) 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
CN102340993A (zh) * 2009-03-03 2012-02-01 爱尔康研究有限公司 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
WO2010101989A1 (en) * 2009-03-03 2010-09-10 Alcon Research, Ltd. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CN102438979A (zh) * 2009-03-12 2012-05-02 麦迪凯姆股份公司 苯甲酰基苯乙酰胺衍生物的新型晶体
KR101543613B1 (ko) 2009-12-03 2015-08-11 알콘 리서치, 리미티드 카복시비닐 폴리머를 포함하는 나노입자 현탁액
JP5998213B2 (ja) 2011-06-28 2016-09-28 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ レゴラフェニブを含有する眼科用局所医薬組成物
CA2840491A1 (en) 2011-06-28 2013-01-03 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing sorafenib
US20130065888A1 (en) 2011-08-15 2013-03-14 Biserka Cetina-Cizmek Ophthalmic formulations and processes for their preparation
GR1007906B (el) * 2012-03-22 2013-05-30 Φαρματεν Αβεε, Οφθαλμικο φαρμακευτικο σκευασμα περιεχον ενα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτου
HK1208162A1 (en) 2012-05-03 2016-02-26 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
HK1204992A1 (en) 2012-06-25 2015-12-11 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing sunitinib
UY35183A (es) 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
CA2900652C (en) 2013-02-15 2021-05-04 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CN107915751A (zh) 2013-02-20 2018-04-17 卡拉制药公司 治疗性化合物和其用途
WO2014160579A1 (en) * 2013-03-25 2014-10-02 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
WO2014207769A1 (en) 2013-06-27 2014-12-31 Mylan Laboratories Ltd Process for the preparation of nepafenac
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
AU2014293665B2 (en) * 2013-07-22 2017-06-01 Eye Care Northwest, Pa Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent
WO2015066482A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN104706579A (zh) * 2015-03-12 2015-06-17 广州仁恒医药科技有限公司 一种夫西地酸滴眼液及其制备方法
CN107708416B (zh) * 2015-05-01 2021-06-29 Onl医疗股份有限公司 肽组合物和使用方法
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324716B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX2019002629A (es) 2016-09-08 2019-10-07 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapéuticos y usos de los mismos.
CA3206106A1 (en) 2021-02-10 2022-08-18 Bhaskar Chaudhuri Methods for ophthalmic delivery of roflumilast
KR102356603B1 (ko) * 2021-08-05 2022-02-08 지엘팜텍주식회사 안구건조증 치료를 위한 레코플라본 함유 점안 조성물
US12263160B2 (en) 2021-09-22 2025-04-01 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
CN114272207B (zh) * 2022-01-21 2023-04-11 山东诺明康药物研究院有限公司 一种纳米晶混悬滴眼液及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313949A (en) * 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
CA1325382C (en) * 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5521222A (en) * 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5369095A (en) * 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
IT1252692B (it) * 1991-11-27 1995-06-23 Zambon Spa Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
US5364884A (en) * 1993-01-21 1994-11-15 Baylor College Of Medicine Arginine compounds as ocular hypotensive agents
US5631005A (en) * 1994-09-21 1997-05-20 Alcon Laboratories, Inc. Use of amidoamines in ophthalmic compositions
US5631004A (en) * 1993-09-30 1997-05-20 Alcon Laboratories, Inc. Use of sustained release antibiotic compositions in ophthalmic surgical procedures
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
US6265444B1 (en) * 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition
NZ334572A (en) * 1997-07-29 1999-08-30 Alcon Lab Inc Conditioning solutions for hard contact lens care comprising one or more galactomannans and a borate compound
US6037328A (en) * 1998-12-22 2000-03-14 Bausch & Lomb Incorporated Method and composition for rewetting and preventing deposits on contact lens
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
EP1249249A1 (en) * 2000-12-12 2002-10-16 Menicon Co., Ltd. Ophthalmic composition
AR030346A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
AR031135A1 (es) * 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
JP2002332225A (ja) * 2001-05-09 2002-11-22 Lion Corp 眼科用組成物
IL161588A0 (en) * 2001-11-01 2004-09-27 Yissum Res Dev Co Method and composition for dry eye treatment
JP2003176228A (ja) * 2001-12-11 2003-06-24 Rohto Pharmaceut Co Ltd 液 剤
US20030133905A1 (en) * 2001-12-20 2003-07-17 Zhenze Hu Composition for treating contact lenses in the eye
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
AU2003217810C9 (en) * 2002-02-28 2008-06-12 Icagen, Inc. Methods for treating diseases related to intraocular pressure
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
US20040115270A1 (en) * 2002-12-13 2004-06-17 Dharmendra Jani Absorption and controlled release of polyethers from hydrogel biomaterials
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
WO2006121964A2 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders

Also Published As

Publication number Publication date
CA2607608A1 (en) 2006-11-16
CY1109117T1 (el) 2014-07-02
BRPI0609227A2 (pt) 2010-03-09
AU2006244244B2 (en) 2010-11-04
US20060257487A1 (en) 2006-11-16
KR20080011310A (ko) 2008-02-01
AU2006244244A1 (en) 2006-11-16
ATE428401T1 (de) 2009-05-15
PT1885336E (pt) 2009-05-07
WO2006121963A3 (en) 2007-03-22
EP1885336B1 (en) 2009-04-15
SI1885336T1 (sl) 2009-08-31
DK1885336T3 (da) 2009-05-25
DE602006006308D1 (de) 2009-05-28
JP4968954B2 (ja) 2012-07-04
WO2006121963A2 (en) 2006-11-16
EP1885336A2 (en) 2008-02-13
ZA200709251B (en) 2009-08-26
CN101175475A (zh) 2008-05-07
CN101175475B (zh) 2010-04-14
PL1885336T3 (pl) 2009-08-31
MX2007014083A (es) 2008-02-07
JP2008540532A (ja) 2008-11-20

Similar Documents

Publication Publication Date Title
AU2006244244B2 (en) Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
EP2049079B1 (en) Compositions containing quaternary ammonium compounds
ES2324058T3 (es) Solucion oftalmica de bimatoprost mejorada.
ES2538479T3 (es) Composiciones oftálmicas y óticas de polímeros y oligómeros facialmente anfifílicos y sus usos
ES2313670T3 (es) Suspension oftalmica que comprende un farmaco oftalmico, una polioxamina y un agente glicolico ajustador de la tonicidad, uso de dicha composicion para la fabricacion de un medicamento para tratar trstornos oftalmicos.
US20140163080A1 (en) Compositions and Methods for Treatment of Glaucoma
CA2934453A1 (en) Compositions and methods for treatment of glaucoma
ES2295161T3 (es) Solucion oftalmica.
ES2341789T3 (es) Composiciones oftalmicas y metodos de uso de las mismas.
WO2005101982A2 (en) A stable ophthalmic composition
JP5072294B2 (ja) アシタザノラスト含有組成物
ES2731754T3 (es) Composición farmacéutica oftalmica que contiene un inhibidor de anhidrasa carbónica y método para la preparación de la misma
JP5514270B2 (ja) アシタザノラスト含有組成物
US20250114375A1 (en) Pharmaceutical composition of lifitegrast and loteprednol etabonate
GR1009616B (el) Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει βρινζολαμιδη και τιμολολη και μεθοδος παρασκευης αυτου
US20170143676A1 (en) Compositions and Methods for Treatment of Glaucoma
HK1165993B (en) Composition containing quaternary ammonium compounds